Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06, Zacks reports. During the same period in the previous year, the firm earned ($0.24) EPS.
Acurx Pharmaceuticals Stock Down 0.3 %
NASDAQ:ACXP traded down $0.01 during midday trading on Thursday, hitting $1.81. The company had a trading volume of 2,140 shares, compared to its average volume of 90,044. The company has a market capitalization of $29.49 million, a PE ratio of -1.67 and a beta of -1.73. Acurx Pharmaceuticals has a 52-week low of $1.52 and a 52-week high of $5.28. The stock’s fifty day moving average price is $1.97 and its 200-day moving average price is $2.14.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Acurx Pharmaceuticals in a research report on Thursday.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Further Reading
- Five stocks we like better than Acurx Pharmaceuticals
- 3 Small Caps With Big Return Potential
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Where to Find Earnings Call Transcripts
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
